Alzheimer's Disease (AD)BBRNCT07912736
BioMIND Biospecimen Repository
An observational study of Alzheimer's Disease (AD) and Cognitive Impairment, run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's at 1 site in Canada.
Trial summary
The purpose of the BBR is to facilitate scientific research by serving as a local and external resource for the distribution of human blood and CSF biospecimens, together with their corresponding clinical data, to internal and external researchers. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Alzheimer's Disease (AD), Cognitive Impairment
- What is being tested?
- blood sample and optional csf collection
- How many people
- 1,000 participants
- Where
- 1 siteCanada
- Study dates
- Nov 2026to 1 Dec 2030
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Eligible patients from the Aging Brain and Memory Clinic (ABMC), Cognitive Neurology, or participants who are enrolled in other research projects affiliated with the Cognitive Clinical Research Group or Cognitive Neurology will be invited to participate in the biorepository. This targeted recruitment strategy ensures that participants have relevant clinical profiles, facilitating efficient enrollment and supporting the study's focus on neurodegenerative conditions.
Who may be able to join
- Written informed consent obtained and documented, either from the participant or the substitute decision-maker.
- Must be a patient from the Aging Brain and Memory Clinic, Cognitive Neurology, or enrolled in other research projects affiliated with the Cognitive Clinical Research Group or Cognitive Neurology.
- Geographic accessibility to the collection site.
- Ability to read, speak, and understand English.
Who cannot join
- Age under 18 years (pediatric population)
- Infectious disease cases such as prion diseases (e.g. Creutzfeldt-Jakob Disease), Human Immunodeficiency Virus, Ebola, or any other pathogen requiring containment above Biosafety Level 1.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: BioMIND Repository for the Collection and Storage of Biospecimens From Individuals With Memory Concerns
The purpose of the BBR is to facilitate scientific research by serving as a local and external resource for the distribution of human blood and CSF biospecimens, together with their corresponding clinical data, to internal and external researchers.
Read the detailed description
The goals for establishing the BBR are to:
- Establish the BBR at Parkwood Institute for the storage and archiving of human blood and CSF.
- Establish a local oversight committee composed of neurologists and community representatives to manage operations, review sample requests, and facilitate local, national, and external collaboration.
- Distribute well-characterized, high-quality biospecimens to internal and external scientific researchers.
- Promote public awareness of the importance of biospecimen collection in supporting brain disease research.
- Conditions
- Alzheimer's Disease (AD), Cognitive Impairment
- Being tested
- blood sample and optional csf collection
- Keywords
- biobank, alzheimer's disease, cognitive impairment
- Medical subject headings
- Alzheimer Disease, Cognitive Dysfunction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
blood sample and optional csf collectionOther
blood sample will be collected at time of consent
What is being measured
The primary outcome is the main question the study is designed to answer.
facilitate scientific research
The purpose of the BBR is to advance neurodegenerative disease research by providing high-quality human blood and cerebrospinal fluid (CSF) biospecimens, together with linked clinical, cognitive, imaging, and biomarker data, to internal and external investigators. Successful outcomes will be measured by the utilization of these resources to support biomarker discovery, validation, and implementation studies aimed at improving the diagnosis, prognosis, monitoring, and treatment of neurodegenerative disorders.
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Nov 2026
- Study startNov 2026 (estimated)
- Primary completion1 Dec 2030 (estimated)
- Study completion1 Dec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Alzheimer's Disease (AD)Studies of the same condition, open and under way.
- More trials run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 1,000 participants (estimated)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jaspreet Bhangu, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07912736
- Sponsor's protocol ID
- BioMIND Biospecimen Repository
- Acronym
- BBR
- Status last verified
- Oct 2026
- First submitted
- 22 Oct 2026
- Last updated
- 3 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- BioMIND Repository for the Collection and Storage of Biospecimens From Individuals With Memory Concerns
- ClinicalTrials.gov ID
- NCT07912736
- Acronym / sponsor ID
- BBR / BioMIND Biospecimen Repository
- Conditions
- Alzheimer's Disease (AD), Cognitive Impairment
- Keywords
- biobank, alzheimer's disease, cognitive impairment
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sUniversity, hospital or other
- Study start
- Nov 2026 (estimated)
- Primary completion
- 1 Dec 2030 (estimated)
- Study completion
- 1 Dec 2030 (estimated)
- First posted
- 3 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the BBR is to facilitate scientific research by serving as a local and external resource for the distribution of human blood and CSF biospecimens, together with their corresponding clinical data, to internal and external researchers.
Detailed description
The goals for establishing the BBR are to:
- Establish the BBR at Parkwood Institute for the storage and archiving of human blood and CSF.
- Establish a local oversight committee composed of neurologists and community representatives to manage operations, review sample requests, and facilitate local, national, and external collaboration.
- Distribute well-characterized, high-quality biospecimens to internal and external scientific researchers.
- Promote public awareness of the importance of biospecimen collection in supporting brain disease research.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Target follow-up
- 1 Day
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Eligible patients from the Aging Brain and Memory Clinic (ABMC), Cognitive Neurology, or participants who are enrolled in other research projects affiliated with the Cognitive Clinical Research Group or Cognitive Neurology will be invited to participate in the biorepository. This targeted recruitment strategy ensures that participants have relevant clinical profiles, facilitating efficient enrollment and supporting the study's focus on neurodegenerative conditions.
Key inclusion criteria (4 listed)
- Written informed consent obtained and documented, either from the participant or the substitute decision-maker.
- Must be a patient from the Aging Brain and Memory Clinic, Cognitive Neurology, or enrolled in other research projects affiliated with the Cognitive Clinical Research Group or Cognitive Neurology.
- Geographic accessibility to the collection site.
- Ability to read, speak, and understand English.
Key exclusion criteria (2 listed)
- Age under 18 years (pediatric population)
- Infectious disease cases such as prion diseases (e.g. Creutzfeldt-Jakob Disease), Human Immunodeficiency Virus, Ebola, or any other pathogen requiring containment above Biosafety Level 1.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| blood sample and optional csf collectionblood sample will be collected at time of consent | Other | – |
Primary outcome
facilitate scientific research
Time frame: 5 years
The purpose of the BBR is to advance neurodegenerative disease research by providing high-quality human blood and cerebrospinal fluid (CSF) biospecimens, together with linked clinical, cognitive, imaging, and biomarker data, to internal and external investigators. Successful outcomes will be measured by the utilization of these resources to support biomarker discovery, validation, and implementation studies aimed at improving the diagnosis, prognosis, monitoring, and treatment of neurodegenerative disorders.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Nov 2026.
- Individual participant dataSharing planned: No
Related trials for Alzheimer's Disease (AD)
RecruitingPhase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
Alzheimer's Disease
RecruitingObservational study
China HEalthy Aging and Dementia Study (HEAD)
Alzheimer Disease (AD), Mild Cognitive Impairment (MCI)
RecruitingPhase 1
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
Alzheimer s Disease, Mild Cognitive Impairment
Recruiting
Automated Language Analysis in Neurodegenerative Diseases: Application of Artificial Intelligence Models
Alzheimer's Disease (AD), Frontotemporal Dementia (FTD)
Not yet recruitingPhase 3
Tricaprilin Phase 3 ALTER-AD (Alternative-Alzheimer Disease) Study
Alzheimer Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Alzheimer's Disease (AD) and Cognitive Impairment, run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 3 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
facilitate scientific research (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Nov 2026.